40 completed, 5 recruiting, 1 active not recruiting, 1 terminated. 24 Phase 1, 10 Phase 3, 8 Phase 2, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 23, Recruiting 1 |
| Phase 3 | 10 | Completed 6, Recruiting 3, Active not recruiting 1 |
| Phase 2 | 8 | Completed 6, Recruiting 1, Terminated 1 |
| Not applicable | 4 | Completed 4 |
Follow Taisho Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis 'TS-172 20~60 mg/day - Hyperphosphatemia Patients on Peritoneal Dialysis | Phase 3 | Recruiting | Taisho Pharmaceutical Co., Ltd. | 30 | 2026-05-13 | 2026-06-10 |
| A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis TS-172 20~60 mg/day - Hyperphosphatemia Patients on Hemodialysis | Phase 3 | Active not recruiting | Taisho Pharmaceutical Co., Ltd. | 34 | 2026-05-08 | 2026-10-06 |
| A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders TS-172 20~60 mg/day, Placebo - Hyperphosphatemia Patients on Hemodialysis | Phase 3 | Recruiting | Taisho Pharmaceutical Co., Ltd. | 100 | 2026-01-09 | 2026-04-17 |
| A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment TS-172 - Patients With Mild or Moderate Hepatic Impairment | Phase 1 | Recruiting | Taisho Pharmaceutical Co., Ltd. | 24 | 2025-12-23 | 2026-01-09 |
| A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis TS-172 - Hyperphosphatemia Patients on Hemodialysis | Phase 3 | Recruiting | Taisho Pharmaceutical Co., Ltd. | 300 | 2025-12-01 | 2025-12-16 |
| A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects TS-172 - Healthy Adult Male Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 16 | 2025-08-05 | 2025-10-03 |
| An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis TS-172 - Patients on Hemodialysis | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 7 | 2025-03-22 | 2025-05-15 |
| A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects Triazolam and TS-172, TS-172 and itraconazole - Healthy Male Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 30 | 2025-03-11 | 2025-05-15 |
| A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects TS-172 20 mg, TS-172 90 mg, Moxifloxacin - Healthy Volunteers | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 52 | 2025-03-03 | 2025-06-06 |
| A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders TS-172, Placebo - Hyperphosphatemia Patients on Hemodialysis | Phase 2 | Completed | Taisho Pharmaceutical Co., Ltd. | 62 | 2025-01-06 | 2025-08-07 |
| A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis TS-172 20~60 mg/day, Placebo - Hyperphosphatemia Patients on Hemodialysis | Phase 3 | Completed | Taisho Pharmaceutical Co., Ltd. | 101 | 2025-01-06 | 2025-11-17 |
| A Mass Balance Study of TS-172 in Healthy Adult Subjects [14C] TS-172 - Healthy Male Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 6 | 2024-09-26 | 2025-02-28 |
| A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects TS-142, Zopiclone, Placebo - Healthy Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 43 | 2023-05-15 | 2025-02-28 |
| A Food Effect Study of TS-142 in Healthy Subjects TS-142 10 mg - Effect of Food | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 12 | 2023-02-15 | 2025-02-28 |
| A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis TS-172 10mg bid, TS-172 30mg bid, TS-172 60mg bid - Hyperphosphatemia Patients on Hemodialysis | Phase 2 | Completed | Taisho Pharmaceutical Co., Ltd. | 326 | 2023-02-08 | 2025-02-28 |
| A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment TS-142 5 mg - Patients with Mild or Moderate Hepatic Impairment | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 84 | 2022-12-26 | 2025-02-28 |
| Long-Term Study of TS-142 in Patients with Insomnia TS-142 5 mg, TS-142 10 mg - Patients with Insomnia | Phase 3 | Completed | Taisho Pharmaceutical Co., Ltd. | 401 | 2022-10-11 | 2025-02-28 |
| Phase III Study of TS-142 in Patients with Insomnia TS-142 5 mg, TS-142 10 mg, Placebo to TS-142 - Patients with Insomnia | Phase 3 | Completed | Taisho Pharmaceutical Co., Ltd. | 1155 | 2022-08-30 | 2025-02-28 |
| A Study in Type 2 Diabetes Patients Who Are Taking Moderate Dose Insulin, Looking at the Effects of the Medication Luseogliflozin on Risk of Ketoacidosis and Insulin Resistance. Luseogliflozin - Diabetes Mellitus Type 2 | Phase 3 | Completed | Aimi Fadilah Mohamad | 40 | 2022-05-01 | 2026-10-15 |
| A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses) TS-172, Placebo - Healthy Adult Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 41 | 2021-08-16 | 2025-02-28 |
Showing 20 of 47. Sign in to see all of them.
Arthritis, Rheumatoid (1) · Depression (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Diabetes Mellitus, Type 2 (1) · Mycobacterium Infections, Nontuberculous (1) · Narcolepsy (1) · Neoplasms (1) · Renal Insufficiency, Chronic (1) · Schizophrenia (1) · Sleep Initiation and Maintenance Disorders (1)
TS-142 (14) · Itraconazole (2) · Moxifloxacin (2) · zopiclone (2) · 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol (1) · BID protein, human (1) · Triazolam (1) · amivantamab (1) · atezolizumab (1) · diclofenac diethylamine (1) · futibatinib (1)
Japan (40) · United States (3) · France (1) · Germany (1) · Indonesia (1) · Italy (1) · Malaysia (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Shigeru Okuyama (9) · Taisho Direcoter (3) · Andri Reza, Dr. Sp.PD-KR (1) · Bambang Setyohadi, Dr. Sp.PD-KR (1) · Carlos A Zarate, M.D. (1) · Cesarius Singgih Wahono, Dr. Sp.PD-KR (1) · Handono Kalim, Dr. Sp.PD-KR (1) · Ika Wulan Yuliani, Dr. Sp.PD-KR (1) · Jordi Rodon, MD (1) · Jun Kato, MD., Ph.D. (1) · Laniyati Hamijoyo, Dr. Sp.PD-KR (1) · Lita Diah Rahmawati, Dr. Sp.PD-KR (1)
PMID 37563858, PMID 30176654, PMID 30813188, PMID 32195934, PMID 34651222, PMID 35193545, PMID 35296912, PMID 39179257, PMID 41001841, PMID 42174196
2017 (1)